OBJECTIVES: Estimating health-related utility weights in Crohn's Disease (CD) patients is crucial for assessing the cost-effectiveness of new pharmaceutical interventions. However, values used in these analyses are usually based on secondary data and vary substantially among studies. We estimated utility weights in a consecutive sample of real-world CD patients. METHODS: Patients enrolled in an ongoing socio-economic study of CD in the Israeli adult patient population completed the self-administered SF-36 questionnaire and were assessed for their current clinical status, including the Harvey-Bradshaw Index (HBI) of disease severity. Patients were classified to one of the four disease states: disease remission (HBI< 5); mild disease (HBI 5-7); moderate disease , and severe disease (HBI> 16). For each patient enrolled we calculated a utility weight using the SF-6D preference-based scoring system developed by Brazier et al. RESULTS: The cohort comprised of 373 patients: (39.4% male), with mean age of 37.8 (±14.2) years, 14.5 (±2.8) years of education, and 11.8 (±9.0) years elapsed since first diagnosis. The average HBI was 6.7 (± 5.6); 148 patients were in remission state, 79 had mild disease, 121 moderate and 25 severe disease. The SF-6D utility weights were correlated with the HBI (-0.341; p< 0.0001). The mean utility weights for each disease state were as follows: disease remission: 0.720 (±0.141); mild disease; 0.700 (±0.123); moderate disease: 0.603 (±0.109); severe disease: 0.531 (±0.135); p< 0.001. The significant predictors of utility weights in a multivariable regression analysis were the HBI (β = -0,440; p< 0.001), years of education (β = 0.104; p= 0.034), and time since diagnosis (β = 0.150; p= 0.007); (R2 = 0.246). CONCLUSIONS: CD patients suffer from a deprived quality of life even in the remission and mild stages of the disease. Utility weights for these patients were generally lower as compared to values used in published cost-effectiveness analyses. These values should be considered when assessing the value for money of future interventions for CD. OBJECTIVES: Eosinophilic Esophagitis (EoE) is an inflammatory disorder that can have an impact on quality of life in individuals. The psychometric properties of the Dysphagia Symptom Questionnaire (DSQ) were assessed in a Phase 2, randomized, double-blind, placebo controlled study of oral budesonide suspension with an open-label extension program. METHODS: The evaluation focused on three items of the DSQ. Psychometric data were analyzed against the FDA guidance and included item level analysis as well as score validation including floor/ceiling, item discrimination, construct validity (concurrent validity and known group's method), test-retest reliability, responsiveness, and calculation of minimally important differences (MID). RESULTS: Patients were 69% male, 62% age ≥ 18, 95% white. Test-retest reliability was strong (r= 0.82). Floor/ceiling levels were below the criteria (≤ 9%) for all items (range 6.5-8.6%). There was strong item discrimination with 98.1% of patients indicating dysphagia in the quartile of DSQ scores. Physician's global ratings of severity and EoE symptom scores were consistent with monotonically increasing DSQ scores. Anchor-based MIDs were 6.5 "a little better" and 13.5 "better" respectively. CONCLUSIONS: The DSQ is a reliable and valid measure able to clinically discriminate patients along the continuum of dysphagia severity. Shanghai, China, 8 GCP ClinPlus Co., Ltd., Beijing, China, 9 Beijing Friendship Hospital, Capital Medical University, Beijing, China OBJECTIVES: To study the variations in self-reported health status of mainland Chinese patients with chronic hepatitis B (CHB) prior to initiating nucleos(t)ide analogues (NUC) treatment. METHODS: This study drew the baseline data of the EVOLVE study, an ongoing observational clinical study of NUCs for treating CHB patients with or without compensated cirrhosis in China. All patients underwent a basket of tests for liver functions and information on their clinical characteristics, life styles, health status (using the EQ-5D-3L questionnaire), and socio-economic status was obtained from medical records or personal interviews. Variations in selfreported health problems and global health were analyzed with logistic and linear regression models, respectively, to identify significant predictors using a stepwise selection method. RESULTS: Two thousand nine hundred and fifty-eight of the 3,434 NUC naïve CHB patients enrolled from 63 hospitals across China (mean age: 39.3 years; male: 73.1%; HBeAg positive: 61.1%; compensated cirrhosis: 20.4%) were included in this analysis. Among those, less than 2% reported problems in mobility, PGi24 cost-effectiveness of interferon-free theraPy for hePatitis c in Germany -an aPPlication of the efficiency frontier aPProach OBJECTIVES: This study reports the long-term cost per sustained virologic response (SVR) with Viekira Pak (ombitasvir, paritaprevir and ritonavir, dasabuvir) with and without ribavirin and standard of care in the US, including sofosbuvir plus simeprevir (SOF+SMV) and sofosbuvir plus peg-interferon and ribavirin (SOF+PR), among patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. METHODS: A Markov cost-effectiveness model was used to estimate the long-term cost of HCV. The analysis modeled independent cohorts of GT1 HCV patients over a lifetime horizon with annual cycles from a US payer perspective. Liver disease progression was assessed based on previous natural history model. Direct medical costs (in 2014 prices and discounted at 3% per year) were obtained from the published literature. Efficacy and safety data were obtained from published clinical trials. SVR rates were stratified by patient treatment history, cirrhosis status, and sub-genotype, where available. Long-term cost per SVR for a patient segment was calculated by dividing total cost of HCV over patient's lifetime by the mean SVR rate in that patient segment. RESULTS: The long-term cost per SVR with Viekira Pak ranged from $88,305 to $94,433 in GT1 non-cirrhotic patients (12-week regimen), $125, $94,433 to $141,413 in GT1a and $88,332 to $125,. and $341, in GT1 cirrhotic patients, all treatment histories combined. Long-term cost per SVR with SOF+PR was $116,713 in GT1a and $134,. CONCLUSIONS: The long-term cost per SVR was lower in non-cirrhotic than in cirrhotic patients across all regimens. The results of this study suggest that the use of Viekira Pak is a clinically and economically viable strategy for GT1 HCV treatment. OBJECTIVES: Hepatic encephalopathy (HE) is a major complication of liver disease and is becoming more problematic in an aging population with cirrhosis. Medicare is a United States (US) government-sponsored health insurance program that guarantees access to healthcare for all individuals 65 or older, or who are younger with disability. The objective of this study was to estimate the annual healthcare expenditures of patients with HE from a Medicare perspective. METHODS: Inpatient, Outpatient, and Master Beneficiary Research Identifiable Files (RIFs) from the Medicare 5% Sample were utilized for this study. Medicare 5% Sample is a nationally representative sample of healthcare claims data for the Medicare population. RIFs include procedure codes, diagnosis codes, reimbursement, and demographic information. To be eligible patients had to have a primary diagnosis code of HE during an inpatient hospitalization. Healthcare utilization/expenditures for inpatient (IP) and outpatient (OP) procedures for the calendar year 2012 were estimated overall and by age cohorts: ≤ 62, 63-67, 68-72, 73-77, 78-82, 83+. RESULTS: A total of 1,113 patients were identified with HE in 2012 (47% were male). 27% of the patients were ≤ 62 years of age while 11% were 83 or older. The most common chronic comorbid condition was hypertension (75%) and 41% had renal failure. The mean total number of visits per HE patient was 13.4 (Mean number of IP and OP visits = 2.4 and 11.0, respectively) and varied across age cohorts 14.6 in the ≤ 62 cohort to 10.7 in the 83+ cohort; p< 0.0001. For patients who had an IP visit the mean length of stay was 5.9 days. Mean inpatient expenditures ranged from $25,364 to $58,625 with the highest
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OBJECTIVES: To study the variations in self-reported health status of mainland Chinese patients with chronic hepatitis B (CHB) prior to initiating nucleos(t)ide analogues (NUC) treatment. METHODS: This study drew the baseline data of the EVOLVE study, an ongoing observational clinical study of NUCs for treating CHB patients with or without compensated cirrhosis in China. All patients underwent a basket of tests for liver functions and information on their clinical characteristics, life styles, health status (using the EQ-5D-3L questionnaire), and socio-economic status was obtained from medical records or personal interviews. Variations in selfreported health problems and global health were analyzed with logistic and linear regression models, respectively, to identify significant predictors using a stepwise selection method. RESULTS: Two thousand nine hundred and fifty-eight of the 3,434 NUC naïve CHB patients enrolled from 63 hospitals across China (mean age: 39.3 years; male: 73.1%; HBeAg positive: 61.1%; compensated cirrhosis: 20.4%) were included in this analysis. Among those, less than 2% reported problems in mobility, PGi24 cost-effectiveness of interferon-free theraPy for hePatitis c in Germany -an aPPlication of the efficiency frontier aPProach 
OBJECTIVES:
The approval of direct-acting antivirals for Interferon-free treatment revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two treatment regimens for genotype 1 infection received approval in the European Union: Sofosbuvir and Ribavirin for 24 weeks and Sofosbuvir and Simeprevir with or without Ribavirin for 12 weeks. We aim to analyze the cost-effectiveness of both regimens in Germany. METHODS: We set up a Markov model with a lifetime horizon to simulate immediate treatment success and long-term disease progression for treatment-naive patients. The model analyzes both shortterm and longterm costs and benefits from the perspective of the German Statutory Health Insurance. We apply the efficiency frontier method, which was suggested by German Institute for Quality and Efficiency in Health Care for cost-effectiveness analysis in Germany. RESULTS: The efficiency frontier is defined by dual therapy and first generation direct-acting antiviral Boceprevir, yielding a maximum of € 1,447.69 per additional percentage point of sustained virologic response gained. Even without rebates, Sofosbuvir/ Simeprevir is very close with € 1,560.13 per additional percentage point. It is both more effective and less expensive than Sofosbuvir/Ribavirin. CONCLUSIONS: In addition to higher sustained virologic response rates, new direct-acting antivirals save long-term costs by preventing complications such as liver cirrhosis, hepatocellular carcinoma and ultimately liver transplants, thereby offsetting part of higher drug costs. Our findings are in line with the guidance published by German Society for Gastroenterology, Digestive and Metabolic Diseases, which recommends Sofosbuvir/Simeprevir for Interferon ineligible or intolerant patients. OBJECTIVES: This study reports the long-term cost per sustained virologic response (SVR) with Viekira Pak (ombitasvir, paritaprevir and ritonavir, dasabuvir) with and without ribavirin and standard of care in the US, including sofosbuvir plus simeprevir (SOF+SMV) and sofosbuvir plus peg-interferon and ribavirin (SOF+PR), among patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. METHODS: A Markov cost-effectiveness model was used to estimate the long-term cost of HCV. The analysis modeled independent cohorts of GT1 HCV patients over a lifetime horizon with annual cycles from a US payer perspective. Liver disease progression was assessed based on previous natural history model. Direct medical costs (in 2014 prices and discounted at 3% per year) were obtained from the published literature. Efficacy and safety data were obtained from published clinical trials. SVR rates were stratified by patient treatment history, cirrhosis status, and sub-genotype, where available. Long-term cost per SVR for a patient segment was calculated by dividing total cost of HCV over patient's lifetime by the mean SVR rate in that patient segment. RESULTS: The long-term cost per SVR with Viekira Pak ranged from $88,305 to $94,433 in GT1 non-cirrhotic patients (12-week regimen), $125,748 (12-week) to $216,520 (24-week) in GT1 cirrhotic patients, $94,433 to $141,413 in GT1a and $88,332 to $125,748 in GT1b treatment-naïve patients (12-week). Long-term cost per SVR with SOF+SMV was $164,725 (12-week) in GT1 non-cirrhotic patients, and $341,569 (24-week) in GT1 cirrhotic patients, all treatment histories combined. Long-term cost per SVR with SOF+PR was $116,713 in GT1a and $134,561 in GT1b naïve patients (12-week). CONCLUSIONS: The long-term cost per SVR was lower in non-cirrhotic than in cirrhotic patients across all regimens. The results of this study suggest that the use of Viekira Pak is a clinically and economically viable strategy for GT1 HCV treatment. OBJECTIVES: Hepatic encephalopathy (HE) is a major complication of liver disease and is becoming more problematic in an aging population with cirrhosis. Medicare is a United States (US) government-sponsored health insurance program that guarantees access to healthcare for all individuals 65 or older, or who are younger with disability. The objective of this study was to estimate the annual healthcare expenditures of patients with HE from a Medicare perspective. METHODS: Inpatient, Outpatient, and Master Beneficiary Research Identifiable Files (RIFs) from the Medicare 5% Sample were utilized for this study. Medicare 5% Sample is a nationally representative sample of healthcare claims data for the Medicare population. RIFs include procedure codes, diagnosis codes, reimbursement, and demographic information. To be eligible patients had to have a primary diagnosis code of HE during an inpatient hospitalization. Healthcare utilization/expenditures for inpatient (IP) and outpatient (OP) procedures for the calendar year 2012 were estimated overall and by age cohorts: ≤ 62, 63-67, 68-72, 73-77, 78-82, 83+. RESULTS: A total of 1,113 patients were identified with HE in 2012 (47% were male). 27% of the patients were ≤ 62 years of age while 11% were 83 or older. The most common chronic comorbid condition was hypertension (75%) and 41% had renal failure. The mean total number of visits per HE patient was 13.4 (Mean number of IP and OP visits = 2.4 and 11.0, respectively) and varied across age cohorts 14.6 in the ≤ 62 cohort to 10.7 in the 83+ cohort; p< 0.0001. For patients who had an IP visit the mean length of stay was 5.9 days. Mean inpatient expenditures ranged from $25,364 to $58,625 with the highest OBJECTIVES: Patients with Clostridium difficileinfection (CDI) can experience longterm symptoms that resemble a chronic disease state. Despite this, a health-related quality of life (HRQOL) instrument specific for patients with CDI does not exist. The goal of this study was to develop and validate a disease specific instrument to assess HRQOL in patients with CDI. METHODS: A systematic literature review was conducted to identify HRQOL instruments and questions related to general health (n= 3) or gastrointestinal disease (n= 13) related to CDI HRQOL. Removing duplicate questions and using direct patient (n= 10) or clinician (n= 10) interviews, a 36-item survey specific to CDI HRQOL was developed. Test-retest and acceptability of item selection was tested on 20 CDI patients and 20 healthy volunteers. The Cdiff36 HRQOL survey was then tested using 100 patients with CDI and compared to the RAND Short-Form 36 (SF-36) Health Survey. Domains containing questions with a correlation coefficient of > 0.7 were considered acceptable. To compare population average scores for patients with CDI, the SF-36 was also administered to 82 patients given broad-spectrum antibiotics. RESULTS: SF-36 scores were significantly higher in healthy controls (72±22) compared to patients on broad-spectrum antibiotics (54±12) or patients with CDI (43±17); p< 0.05 each vs. control. The final version of the Cdiff36 contained six domains: daily activities (4 items), anxiety (3 items), diet (3 items), sleep (2 items), discomfort (6 items), health perception (6 items), dysphoria (6 items), relationship (2 items), and social interaction (3 items). CDiff36 scores correlated significantly based on recurrence vs. primary CDI as well as time since last episode (p< 0.05, each). Cdiff36 scales also correlated significantly with the SF-36. CONCLUSIONS: The properties of the Cdiff36 should make it appropriate to assess changes over time in HRQOL in patients with CDI. Future language translations and validation will be required for global use of the CDiff36.
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OBJECTIVES: The Food and Drug Administration's (FDA) clinical trial guidelines for development of patient reported outcome (PRO) instruments recommends deriving the PRO concepts from the target population using qualitative research. Since the PRO instruments currently used in clinical trials of hepatitis C (HCV) patients are not developed specifically for this patient population, the FDA's recommendation is not fulfilled. The purpose of this study was to identify a comprehensive list of health related quality of life (HRQoL) themes that may be unique to HCV by reviewing qualitative studies of HCV patients. METHODS: Ovid Medline, Ovid Embase, Ovid PsycINFO, and PubMed were searched for peer-reviewed journals from 1946 to 2012. Inclusion criteria required primary studies to include HCV patients; be published in English; and used qualitative methods to report an aspect of the HCV experience. Studies were excluded if secondary data was used or there were proxy views. Included studies were graded on study quality using the Qualitative Assessment and Review Instrument. Eligible studies were then analyzed using meta-synthesis; findings from individual studies were grouped into themes which were combined to generate HRQoL domains. RESULTS: Ten studies met the inclusion/exclusion criteria and the quality assessment criteria and were included for review. Eleven themes were identified: physical symptoms, physical activities, guilt, stigma, emotional distress, psychological behavior, social relationship, social activities, work function, sexual function, and cognitive function. The type of themes identified in each study varied by the focus of the primary study and the analytical framework used in the qualitative studies. The themes were further grouped into six HRQoL domains: physical, psychological/emotional, social, work, sexual, and cognitive functionality. CONCLUSIONS: The systematic review represents a useful starting point in the critical appraisal of the PRO instruments used for clinical trials in HCV patients. 
Gastrointestinal
OBJECTIVES:
We assessed the impact on prescription behaviors and drug expenditures of an outpatient prescription incentive program in South Korea that provides financial incentives to primary care physicians for less prescription of medicines. METHODS: We focused on drugs for ulcer or gastro-esophageal reflux disease. National Health Insurance claims data for years 2009~2012 were extracted from 1,625 clinics. A clinic-level random effects model was used. RESULTS: The overall impact of the program on drug expenditure was not significant. However, clinics in general medicine showed a lower prescription rate (-0.8 percentage points), number of medicines prescribed (-0.02), prescription duration (-0.15 days), and monthly drug expenditure (-740 won) per claim after the policy. Small clinics had lower drug expenditure (-650 won) and prescription duration (-0.76 days), while large clinics and those in group practice had higher prescription rate (+1.5 and 2.5 percentage points, respectively) and number of medicines prescribed (+0.03, group practice only) after the policy. CONCLUSIONS: The outpatient prescription incentive program worked as intended only in subgroups of minor clinics for the target medicines. self-care, or usual activities; 15.8% and 16.5% reported pain/discomfort and anxiety/ depression, respectively. The mean (standard deviation) global health score was 83.5 (13.3) on a 0 (worst) to 100 (best) scale. Independent predictors of reporting any of the EQ-5D health problems included female gender, BMI 25-30 kg/m2, presence of comorbidity (hypertension, hyperlipidemia, etc.), family history of liver cancer, albumin < 28g/L, and HBeAg positive. Alcohol drinking, a diagnosis of CHB for > 15 years, and presence of comorbidity were independent predictors of a lower global health score, with the effect size ranging between 1 and 4 points. CONCLUSIONS: CHB characteristics showed some association with patient-reported health problems, but their association with general health perception was minimal. The modest relationship between clinical and patient-reported outcomes measures supports the assessment of patient-reported outcomes in patients with CHB. 
PGi30
